Xiang Boni, Tao Ran, Liu Xinhua, Zhu Xiaoming, He Min, Ma Zengyi, Yang Yehong, Zhang Zhaoyun, Li Yiming, Yao Zhenwei, Wang Yongfei, Ye Hongying
Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Endocr Connect. 2019 Aug 1;8(8):1176-1185. doi: 10.1530/EC-19-0309.
The aim of this study was to evaluate thyroid functions in Cushing's syndrome (CS), the dynamic changes of thyroid hormones and antithyroid antibodies in Cushing's disease (CD) pre- and postoperatively.
This is a retrospective study enrolling 118 patients with CS (102 CD, 10 adrenal CS and 6 ectopic adrenocorticotropic syndrome (EAS)). Thyroid functions (thyroid-stimulation hormone (TSH), T3, free T3 (FT3), T4 and free T4 (FT4)) were measured in all CS at the time of diagnosis and in all CD 3 months after transsphenoidal pituitary tumor resection. Postoperative hormone monitoring within 3 months was conducted in 9 CD patients completing remission. Twenty-eight remitted CD patients experienced hormone and antithyroid antibody evaluation preoperatively and on the 3rd, 6th and 12th month after surgery.
TSH, T3 and FT3 were below the reference range in 31%, 69% and 44% of the 118 CS patients. Remitted CD patients (81/102) had significantly higher TSH (P = 0.000), T3 (P = 0.000) and FT3 (P = 0.000) than those in the non-remission group (21/102). After remission of CD, TSH, T3 and FT3 showed a significant increase, with a few cases above the reference range. By 12 months, most CD patients' thyroid functions returned to normal. Thyroid hormones (including TSH, T3 and FT3) were negatively associated with serum cortisol levels both before and after surgery. No significant changes of antithyroid autoantibodies were observed.
TSH, T3 and FT3 are suppressed in endogenous hypercortisolemia. After remission of CD, TSH, T3 and FT3 increased significantly, even above the reference range, but returned to normal 1 year after surgery in most cases. Antithyroid antibodies did not change significantly after remission of CD.
本研究旨在评估库欣综合征(CS)患者的甲状腺功能,以及库欣病(CD)患者术前和术后甲状腺激素及抗甲状腺抗体的动态变化。
这是一项回顾性研究,纳入了118例CS患者(102例CD、10例肾上腺性CS和6例异位促肾上腺皮质激素综合征(EAS))。在所有CS患者确诊时以及所有CD患者经蝶窦垂体肿瘤切除术后3个月测量甲状腺功能(促甲状腺激素(TSH)、T3、游离T3(FT3)、T4和游离T4(FT4))。对9例实现缓解的CD患者在术后3个月内进行激素监测。28例缓解的CD患者在术前以及术后第3、6和12个月进行了激素及抗甲状腺抗体评估。
118例CS患者中,31%的患者TSH、69%的患者T3和44%的患者FT3低于参考范围。缓解的CD患者(81/102)的TSH(P = 0.000)、T3(P = 0.000)和FT3(P = 0.000)显著高于未缓解组(21/102)。CD缓解后,TSH、T3和FT3显著升高,少数病例高于参考范围。到12个月时,大多数CD患者的甲状腺功能恢复正常。术前和术后甲状腺激素(包括TSH、T3和FT3)均与血清皮质醇水平呈负相关。未观察到抗甲状腺自身抗体有显著变化。
内源性高皮质醇血症时TSH、T3和FT3受到抑制。CD缓解后,TSH、T3和FT3显著升高,甚至高于参考范围,但大多数病例在术后1年恢复正常。CD缓解后抗甲状腺抗体无显著变化。